Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16076275 | 1.00 | CYP2C9 (0.48) | CYP2C9 | |
| SCHEMBL14872327 | 1.00 | CYP2C9 (0.48) | CYP2C9 | |
| SCHEMBL16033261 | 1.00 | CYP2C9 (0.48) | CYP2C9 | |
| SCHEMBL1841914 | 1.00 | CYP2C9 (0.48) | CYP2C9 | |
| SCHEMBL16033260 | 1.00 | CYP2C9 (0.48) | CYP2C9 | |
| Bromide SCHEMBL16782421 | 0.97 | CYP2C9 (0.46) | CYP2C9 | |
| Bromide SCHEMBL16148885 | 0.97 | CYP2C9 (0.46) | CYP2C9 | |
| Hydrochloric Acid SCHEMBL16033819 | 0.97 | CYP2C9 (0.46) | CYP2C9 | |
| SCHEMBL15466711 | 0.72 | — | — | |
| SCHEMBL7363814 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-11 | — | — | US | disclosed |
| EP-3983401-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | Arkuda Therapeutics (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-113950477-A | Modulators of progranulin and methods of use thereof | 阿库达医疗公司 | 2022-01-18 | — | — | CN | disclosed |
| US-9359356-B2 | Azaadamantane formate ester and process for preparing azaadamantane derivatives | ABBVIE INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20150166541-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | ABBVIE INC. | 2015-06-18 | — | — | US | disclosed |
| US-8969562-B2 | Azaadamantane formate ester and process for preparing azaadamantane derivatives | ABBVIE, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140275546-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | ABBVIE INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166541-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | DHRS9, GRHPR, DECR1 | CYP2C9 266/4885 |
| US-20220251084-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PRNP, PSEN2 | CYP2C9 4856/4885 |
| US-20140275546-A1 | AZAADAMANTANE FORMATE ESTER AND PROCESS FOR PREPARING AZAADAMANTANE DERIVATIVES | DHRS9, GRHPR, DECR1 | CYP2C9 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.